The information provided by GHD in any form is not intended to substitute medical advice but rather serve as a guide and an informational platform for various available treatments and options for such. Reliance on any information provided by GHD Website, its employees, consultants or any other person on its behalf is solely at your own risk and discretion.

© 2020 by Global Healthcare Direct Limited

CAR T-Cell Immunotherapy for Recurrent/Refractory Acute Myeloid Leukemia (AML) 

Phase I/II Clinical Trial

Patients with relapsed or refractory acute myeloid leukemia (AML) often develop resistance to chemotherapy. For this reason, the investigators are attempting to use T-cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR) to CD123, expressed on the surface of the cell in patients with CD123+ AML. The CAR enables the T-cell to recognize and kill the cell through the recognition of CD123, a protein expressed on the surface of the cell in patients with CD123+ leukemia. This is a Phase I/II study designed to evaluate the safety and efficacy of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of CD123+ leukemia.

Phase I/II Open Clinical Trial 

Through both our partner hospitals in Beijing and the trial sponsor, Hebei Senlang BIOTECHNOLOGY Co., LTD, we at Global Healthcare Direct gained a direct access to the clinical trial recruitment process. 

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 100 participants
Intervention Model Description: Single Group Assignment
Masking: Open-label trial
Primary Purpose: Treatment

How to apply for the Acute Myeloid Leukemia (AML) CAR-T trial?

Fill in the below form. Add a short description of your case history and of your current condition. Our case manager will contact you shortly and guide you through.

Choosing to participate in a medical trial is an important personal decision.

Talk with your doctors and family members or friends about deciding to join a study!

Attach a document
Max File Size 25MB

Inclusion Criteria

(The results of the examination after patients admitted in hospital are the mainly criteria for admission)

  • Be diagnosed a kind of Relapsed or Refractory CD123+ AML;

  • ECOG score≤2;

  • To be aged 3 to 70 years;

  • More than a month lifetime from the consent signing date.


Exclusion Criteria

  • Serious cardiac insufficiency, left ventricular ejection fraction<50%;

  • Has a history of severe pulmonary function damaging;

  • Merging other progressing malignant tumor;

  • Merging uncontrolled infection;

  • Merging the metabolic diseases (except diabetes);

  • Merging severe autoimmune diseases or immunodeficiency disease;

  • Patients with active hepatitis B or hepatitis C;

  • Patients with HIV infection;

  • Has a history of serious allergies on Biological products (including antibiotics);

  • Pregnancy or lactation women;

  • Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.

* The Criteria is finally evaluated by Investigators.

What's next?

  1. Contact us: fill this form, send an email or give us a call.

  2. Send us your medical documents. We will translate and forward them to the hospital's experts.

  3. We will send you the various possible treatment plans and prices, and help you select the best option for you.

  4. If you’d like, we can help in organizing your flights and accommodation.

  5. Our personal attendant will meet you at the arrival gate and accompany you throughout the course of your treatment.

  6. We will send the translated release documents and keep in touch with you even after you leave.


Always here for you,

The GHD Team 

Attach a document
Max File Size 25MB